John Oconnell, MD
Radiation Oncology · Greenville, SCNPI 1952455768
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,500 of the $5,779 with a category attached, or 77.9%. Abbott accounts for 77.9% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $4,645 and has fallen 97.2% since, to $130 in 2025.
Across 45 payments — averaging $128.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- AstraZeneca$186
- Takeda Pharmaceuticals U.S.A., Inc.$140
- Pfizer$136
- Boston Scientific$131
- E.r. Squibb & Sons, L.L.C.$114
- plus $572 from 19 others
Across 1 payment — averaging $5000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure GmbH$5K
What the payments were for
- Consulting fees$4,50078%
- Food & beverage$1,27922%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 1 | $4,500 |
| AstraZeneca(2 entities) | 4 | $186 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $140 |
| Pfizer | 5 | $136 |
| Boston Scientific | 2 | $131 |
| E.r. Squibb & Sons, L.L.C. | 1 | $114 |
| Servier Pharmaceuticals LLC | 4 | $87 |
| Seagen Inc. | 2 | $48 |
| Tactile Systems Technology Inc | 3 | $47 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Bayer | 2 | $44 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $41 |
| Incyte Corporation | 2 | $32 |
| Stemline Therapeutics Inc. | 1 | $26 |
| Eisai Inc. | 1 | $23 |
| Blueprint Medicines Corporation | 1 | $19 |
| Blue Earth Diagnostics | 1 | $17 |
| Novocure Inc. | 1 | $16 |
| Brainlab, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Sobi, Inc | 1 | $14 |
| EMD Serono, Inc. | 1 | $14 |
| Morphosys, US Inc. | 1 | $13 |
| Olympus America Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cardiovascular- Research only$4,500
- LYNPARZA$125
- GENERAL - THERAPIES$118
How this compares
$5,779 in reported general payments places this provider in the 85th percentile of 72 radiation oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 12 | $33,478 |
| Hydrocortisone | 75 | $659 |
| Dexamethasone | 11 | $372 |
| Bicalutamide | 16 | $364 |
| Lorazepam | 11 | $16 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx | $44 | $33,47812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 72 radiation oncology providers in South Carolina.
Other radiation oncology in Greenville
- Samuel FaughtGreenville$2K
- Emory McTyreGreenville$2K
- Michael GreenbaumGreenville$2K
- Shirnett MatthewsGreenville$2K
- Michael ZurenkoGreenville$940
- Jennifer VogelGreenville$222
- Daniel FriedSpartanburg$57K
- Clinton MedberyCharleston$37K
- Brian LallyCharleston$29K
- Kurt MeyerColumbia$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.